/

Eyconis

Develops long-acting biopharmaceutical treatments for retinal diseases.

BiotechnologyPharmaceuticals eyconis.com ↗

Company facts

Founded: 2023
Employees: 39
Headquarters: United States
Type: Private
Funding: Series C · $25M · 2025